EcoDrugPlus

Adrenoceptor Alpha 2a

Ensembl ID : ENSPFOG00000019902
Gene Symbol: ADRA2A
1 Cross references
176 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSPFOG00000020919
Gene Symbol: ADRA2A
1 Cross references
159 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSPFOG00000020690
Gene Symbol: ADRA2C
1 Cross references
159 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSPFOG00000020689
Gene Symbol: ADRA2C
1 Cross references
159 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSPFOG00000006254
Gene Symbol: ADRA2C
2 Cross references
157 Possible Orthologues:

Adrenoceptor Beta 1

Ensembl ID : ENSPFOG00000020184
Gene Symbol: ADRB1
3 Cross references
161 Possible Orthologues:

Adrenoceptor Beta 2

Ensembl ID : ENSPFOG00000007036
Gene Symbol: ADRB2
1 Cross references
192 Possible Orthologues:

Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase), Tandem Duplicate 1

Ensembl ID : ENSPFOG00000014667
Gene Symbol: AKR1B1.1
1 Cross references
345 Possible Orthologues:

Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase), Tandem Duplicate 2

Ensembl ID : ENSPFOG00000014569
Gene Symbol: AKR1B1.2
1 Cross references
343 Possible Orthologues:

Alpha Glucosidase

Ensembl ID : ENSPFOG00000007744
Gene Symbol: GAA
3 Cross references
234 Possible Orthologues:

Alpha-1a Adrenergic Receptor

Ensembl ID : ENSPFOG00000014983
Gene Symbol: LOC103146394
3 Cross references
202 Possible Orthologues:

Alpha-2b Adrenergic Receptor

Ensembl ID : ENSPFOG00000010343
Gene Symbol: LOC103145863
3 Cross references
174 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).